Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Oncocyte Corp (OCX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K/A Quarterly results
10/05/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "ONCOCYTE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS"
07/24/2023 8-K Quarterly results
07/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT , is entered into effective July 13, 2023 by and between Oncocyte Corporation , a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs . WHEREAS, the Company and Executive previously entered into that certain Amended and Restated Employment Agreement, effective May 1, 2023 ; WHEREAS, pursuant to Section 12 of the Employment Agreement, the Employment Agreement may be amended, in writing, signed by both the Company and Executive; WHEREAS, the Company and Executive desire to amend the Employment Agreement as set forth herein; and WHEREAS, capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Employment Agreement. NOW, THEREFORE, in ..."
07/10/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/30/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/29/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT is entered into as of June 6, 2023, by and between Oncocyte, Corporation , a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs ."
06/06/2023 8-K Investor presentation
05/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/11/2023 8-K Quarterly results
Docs: "ONCOCYTE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/13/2023 8-K Quarterly results
04/05/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/05/2023 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
03/31/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ONCOCYTE REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS"
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer"
02/23/2023 8-K Asset disposition
Docs: "Second AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT is adopted as of the 16th day of February, 2023 , by and among Oncocyte Corporation, a California corporation , Dragon Scientific, LLC, a Delaware limited liability company , and Razor Genomics, Inc., a Delaware corporation . Seller, Company, and Buyer are referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Stock Purchase Agreement . WHEREAS, Buyer, Seller and the Company have entered into that certain Stock Purchase Agreement, dated as of December 15, 2022 and amended the same pursuant to that certain First Amendment to Stock Purchase Agreement entered into as...",
"ONCOCYTE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 16, 2023, Oncocyte Corporation completed its sale of 3,188,181 shares of common stock of its wholly-owned subsidiary Razor Genomics, Inc. , which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, pursuant to a previously announced Stock Purchase Agreement with Dragon Scientific, LLC, a Delaware limited liability company , and Razor, a Delaware corporation . In connection with the Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx TM , a test used to predict a patient’ s risk of cancer recurrence following surgery and response to chemotherapy in early-stage lung cancer. Following the Closing...",
"ONCOCYTE COMPLETES RAZOR GENOMICS TRANSACTION"
02/14/2023 SC 13G/A PURA VIDA INVESTMENTS, LLC reports a 15.2% stake in Oncocyte Corp
02/14/2023 SC 13G PURA VIDA INVESTMENTS, LLC reports a 15.2% stake in Oncocyte Corp
02/14/2023 SC 13G AWM Investment Company, Inc. reports a 6.1% stake in OncoCyte Corporation
02/13/2023 8-K Quarterly results
02/03/2023 8-K Quarterly results
01/30/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
12/21/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/23/2022 SC 13G Norfield Capital LLC reports a 5.5% stake in Oncocyte Corporation
11/23/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy